Studies have shown that the combination of osimertinib and gefitinib has consistent efficacy as a first-line treatment for EGFR-mutated NSCLC, which provides insights into the use of dual EGFR-TKIs (52). This evidence concerns the gene EGFR and non-small cell lung carcinoma.